Skip to main content
. 2021 Sep 30;11:19422. doi: 10.1038/s41598-021-97236-0

Figure 5.

Figure 5

V56B2 retains full anti-TNFα and anti-IL-23 activity. (A) V56B2 and the trypsin-liberated V565 monomer arm were tested alongside the V565 parent in the biotinylated adalimumab competition ELISA. Biotinylated adalimumab in the absence of Vorabody was added as a control (B) V56B2 and the trypsin-liberated V900 monomer arm were also tested alongside the V900 parent in the IL-23/IL-23R ELISA. IL-23 in the absence of Vorabody was added as an assay control. Error bars =  +/− SD. N = 3.